These trials completed more than 12 months ago and should have reported results.

These trials are not yet due to report results: some are ongoing, some completed within the past 12 months.

These trials have problematic data on the registry. Details why »

Status Trial ID Title Completion date Category
Ongoing 2015-005758-36 A Phase 3, Randomized Study to Assess the Efficacy and Safety of Ublituximab in Combination with TGR-1202 (Umbralisib) Compared to Obinutuzumab in Combination with Chlorambucil in Patients with Chroni... not-yet-due
Other 2016-004339-19 A Multi-Center, Open-Label, Extension Study of Ublituximab (TG-1101) in Combination with TGR-1202 for Patients Previously Enrolled in Protocol UTX-TGR-304 not-yet-due
Other 2016-004718-90 A Phase 2b Randomized Study to Assess the Efficacy and Safety of the Combination of Ublituximab + TGR-1202 with or without Bendamustine and TGR-1202 alone in Patients with Previously Treated Non-Hodgk... not-yet-due
Listed as ongoing, but also has a completion date 2017-000638-75 Phase III: UbLiTuximab In Multiple Sclerosis Treatment Effects (ULTIMATE I STUDY) 2020-11-06 bad-data
Listed as ongoing, but also has a completion date 2017-000639-15 Phase III: UbLiTuximab In Multiple Sclerosis Treatment Effects (ULTIMATE II STUDY) 2020-11-12 bad-data
Ongoing 2019-003625-16 An Open Label Extension Study of Ublituximab in Subjects with Relapsing Multiple Sclerosis Otvoreni nastavak kliničkog ispitivanja Ublituximaba u ispitanika s relapsnom multiplom sklerozom not-yet-due